Patents Assigned to New England Medical Center Hospitals, Inc.
-
Patent number: 5322936Abstract: Disclosed is recombinant penetrin polypeptide. Also disclosed is nucleic acid encoding penetrin, recombinant cells and plasmids encoding penetrin, antibodies directed against penetrin and various uses for penetrin and antibodies directed against penetrin.Type: GrantFiled: August 6, 1993Date of Patent: June 21, 1994Assignee: New England Medical Center Hospitals, Inc.Inventors: Miercio E. A. Pereira, Eduardo Ortega-Barria
-
Patent number: 5296090Abstract: A detector assembly for use in obtaining alpha-track autoradiographs, the detector assembly including a substantially boron-free substrate; a detector layer deposited on the substantially boron-free substrate, the detector layer being capable of recording alpha particle tracks and exhibiting evidence of the alpha tracks in response to being exposed to an etchant, the detector layer being less than about 2 microns thick; and a protective layer deposited on the detector layer, the protective layer being resistant to the etchant and having a thickness of about 0.5 to 1 microns.Type: GrantFiled: December 3, 1991Date of Patent: March 22, 1994Assignees: New England Medical Center Hospitals, Inc., Massachusetts Institute of TechnologyInventors: Guido Solares, Robert G. Zamenhof
-
Patent number: 5286847Abstract: Disclosed are novel muteins of IL-1 compounds which can be used to regulate excess IL-1 produced in various diseases in humans and animals. The IL-1 muteins can be prepared by site-directed mutagenesis whereby a positively charged residue is replaced with a negatively charged or neutral residue at a designated position in the molecule. The resulting IL-1 muteins have reduced biological activity but retain receptor binding affinity.Type: GrantFiled: May 19, 1992Date of Patent: February 15, 1994Assignees: New England Medical Center Hospitals, Inc., Massachusetts Institute of TechnologyInventors: Lee Gehrke, Philip E. Auron, Lanny Rosenwasser
-
Patent number: 5277188Abstract: A clinical information reporting system for use with an electronic database for a health care facility, the electronic database containing records for a group of patients and operational information which is accessed and used during the course of operation of the facility, the records containing clinical information for said group of patients, the reporting system including an electrocardiograph which generates ECG-related data for the group of patients; database application logic for incorporating the ECG-related data for the group of patients into the database; and report generating logic for generating a process of care report from the information stored in the database, the process of care report presenting selected process of care information derived from the database as a function of a clinically meaningful class of the group of patients, wherein the clinically meaningful class is defined at least in part in terms of the ECG-related data supplied by the electrocardiograph and stored within the database.Type: GrantFiled: June 26, 1991Date of Patent: January 11, 1994Assignee: New England Medical Center Hospitals, Inc.Inventor: Harry P. Selker
-
Patent number: 5276612Abstract: A risk management system for use in a health care facility which receives patients who may be experiencing cardiac problems, the system including a first input port for receiving inputs derived from electrocardiograph measurements of a patient; a predictive instrument for using the inputs to compute a probability of the patient having a particular heart condition; a printer for generating a risk management form reporting the computed probability for the patient as well as other clinical and ECG-related observations for the patient, the form also containing categories requiring a person who is evaluating the patient to enter additional information relating to the evaluation of the patient, the computed probability triggering the printer to generate the form only when the computed probability falls within a preselected range which is less than the total range of possible values for the computed probability.Type: GrantFiled: September 21, 1990Date of Patent: January 4, 1994Assignee: New England Medical Center Hospitals, Inc.Inventor: Harry P. Selker
-
Patent number: 5270052Abstract: A method for treating an infection caused by an intracellular parasite in a patient. The method includes administering to the patient liposomes coated with C-reactive protein, wherein the liposomes include phosphatidylcholine or phosphorylcholine.Type: GrantFiled: April 19, 1991Date of Patent: December 14, 1993Assignee: New England Medical Center Hospitals, Inc.Inventors: Jeffrey A. Gelfand, Michael V. Callahan, Yoshinori Yamada
-
Patent number: 5252556Abstract: A fragment capable of binding to an anti-CD43 autoantibody made by a human infected with HIV-1. The fragment, which includes a part or the entirety of an amino acid sequence corresponding to positions 20-254 of CD43, can be used in treatment or diagnosis of HIV-1 infections.Type: GrantFiled: March 30, 1990Date of Patent: October 12, 1993Assignee: New England Medical Center Hospitals, Inc.Inventor: Blair Ardman
-
Patent number: 5252712Abstract: Antibodies which form immune complexes with human native prothrombin only, in the presence of mixtures of human native prothrombin and human abnormal prothrombin as well as antibodies which form antibody antigen complexes with human abnormal prothrombin in the presence of such mixtures have been obtained. Immunoassay techniques are used for qualitative and quantitative determinations of these antigens in human plasma or serum. Unique methods of obtaining the antibodies are described including obtaining antibodies to native prothrombin by dissociation of antigen antibody complexes formed in the presence of calcium ions with a material having a greater affinity constant for binding with calcium ions than does prothrombin. Dissociation of the complex in this manner yields human native prothrombin antibodies which are specific and non-reactive with human abnormal prothrombin.Type: GrantFiled: August 3, 1988Date of Patent: October 12, 1993Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce E. Furie, Barbara C. Furie, Rita A. Blanchard
-
Patent number: 5234822Abstract: Disclosed is recombinant penetrin polypeptide. Also disclosed is nucleic acid encoding penetrin, recombinant cells and plasmids encoding penetrin, antibodies directed against penetrin and various uses for penetrin and antibodies directed against penetrin.Type: GrantFiled: October 17, 1991Date of Patent: August 10, 1993Assignee: New England Medical Center Hospitals, Inc.Inventors: Miercio E. A. Pereira, Eduardo Ortega-Barria
-
Patent number: 5219990Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.Type: GrantFiled: January 28, 1991Date of Patent: June 15, 1993Assignees: Biogen, Inc., New England Medical Center Hospitals, Inc.Inventors: Elliot J. Androphy, James G. Barsoum
-
Patent number: 5212168Abstract: A method for treating glaucoma consisting of exposing the eye to a corticosteroid and an alpha or a beta adrenergic agent to the eye which acts to decrease ocular pressure. Useful adrenergic agents include beta agonist antagonists, including, for example, epinephrine, dipivalyl epinephrine, betaxolol, levobunolol, timolol, and an alpha adrenergic agonist, including apraclonidine hydrochloride. Useful steroids, which are preferably applied topically, include dexamethasone, prednisolone, cortisone, and triamcinolone. The beta adrenergic agent is administered at a concentration between 10% and 20% of the concentration that the agent is administered in its normal use. The corticosteroid is administered at a concentration between 5% and 10% of the concentration that the corticosteroid is administration in its normal use.Type: GrantFiled: February 26, 1991Date of Patent: May 18, 1993Assignee: New England Medical Center Hospital, Inc.Inventor: Bernard Schwartz
-
Patent number: 4998535Abstract: An instrument for predicting the benefit of using thrombolytic therapy to treat a patient with a heart condition including a first input port for receiving inputs derived from electrocardiograph measurements of the patient's condition, and a processor for computing an estimate of said benefit based upon the electrocardiograph-derived inputs.Type: GrantFiled: September 5, 1989Date of Patent: March 12, 1991Assignees: Univ. of Washington New England Medical Center Hospitals, Inc., Duke UniversityInventors: Harry P. Selker, Galen S. Wagner, W. Douglas Weaver, Robert M. Califf
-
Patent number: 4935493Abstract: A compound having the structure ##STR1## where T is of the fomrula ##STR2## where each D.sup.1 and D.sup.2, independently, is a hydroxyl group of a group which is capable of being hydrolysed to a hydroxyl group in aqueous solution at physiological pH; a group of the formula ##STR3## where G is either H,F or an alkyl group containing 1 to about 20 carbon atoms and optional heteroatoms which can be N, S, or O; or a phosphonate group of the formula ##STR4## where J is O-alkyl, N-alkyl, or alkyl, each comprising about 1-20 carbon atoms and, optionally, heteroatoms which can be N, S, or O; T being able to form a complex with the catalytic site of an enzyme, X is a group having at least one amino acid, ##STR5## and each R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 is separately a group which does not interfere significantly (i.e., does not lower than Ki of the compound to less than 10.sup.Type: GrantFiled: October 6, 1987Date of Patent: June 19, 1990Assignees: E. I. Du Pont de Nemours and Company, New England Medical Center Hospitals, Inc., Tufts UniversityInventors: William W. Bachovchin, Andrew G. Plaut, Charles A. Kettner
-
Patent number: 4923807Abstract: The invention is directed to an Arg-Serpin human plasminogen activator inhibitor designated PAI-2. This protein is prepared via recombinant DNA means. The invention also includes other serpins which can be made by amino acid substitutions or deletions in conserved regions of PAI-1 and PAI-2, as shown in FIG. 4. The proteins of the invention can be used to inhibit, or at least modulate, human plasminogen activator activity in a variety of physiological conditions, e.g., fibrinolysis, tumor metastasis, and tumor growth.Type: GrantFiled: February 6, 1987Date of Patent: May 8, 1990Assignees: New England Medical Center Hospitals Inc., Tufts College, Wellesley College, MITInventors: Andrew C. Webb, Philip E. Auron
-
Patent number: 4904649Abstract: A method for treating glaucoma consisting of exposing the eye to a corticosteroid and a beta adrenergic agent to the eye which acts to decrease ocular pressure. Useful adrenergic agents include beta agonists antagonists, including, for example, epinephrine, dipivalyl epinephrine, betaxolol, levobunolol, and timolol. Useful steroids, which are preferably applied topically, include dexamethasone, prednisolone, cortisone, and triamcinolone. The beta adrenergic agent is administered at a concentration between about 10% and 20% of the concentration that the agent is administered in its normal use. The corticosteroid is administered at a concentration between 5% and 10% of the concentration that the corticosteroid is administered in its normal use.Type: GrantFiled: March 27, 1987Date of Patent: February 27, 1990Assignee: New England Medical Center Hospitals, Inc.Inventor: Bernard Schwartz
-
Patent number: 4839281Abstract: A biologically pure culture of a strain of bacteria of a Lactobacillus species in which the bacteria have avid adherence to intestinal cells, are able to survive at low pH, and produce large amounts of lactic acid.Type: GrantFiled: April 17, 1985Date of Patent: June 13, 1989Assignee: New England Medical Center Hospitals, Inc.Inventors: Sherwood L. Gorbach, Barry R. Goldin
-
Patent number: 4832483Abstract: A method for determining the presence of malignancy disease in a subject person includes obtaining a test sample of blood plasma from the person, measuring intensities of Raman scattering from the plasma at frequencies in the frequency shift range between 1000 cm.sup.-1 and 1600 cm.sup.-1, and comparing the intensities to intensities of Raman scattering, at comparable frequencies, from normal human plasma.Type: GrantFiled: September 3, 1987Date of Patent: May 23, 1989Assignee: New England Medical Center Hospitals, Inc.Inventor: Surendra P. Verma
-
Patent number: 4783330Abstract: An antibody reactive with activated human platelets, and substantially unreactive with resting human platelets, with the azurophilic granules of monocytes, and with granulocytes.Type: GrantFiled: November 8, 1985Date of Patent: November 8, 1988Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce E. Furie, Barbara C. Furie
-
Patent number: 4769320Abstract: Antibodies which form immune complexes with human native prothrombin only, in the presence of mixtures of human native prothrombin and human abnormal prothrombin as well as antibodies which form antibody antigen complexes with human abnormal prothrombin in the presence of such mixtures have been obtained. Immunoassay techniques are used for qualitative and quantitative determinations of these antigens in human plasma or serum. Unique methods of obtaining the antibodies are described including obtaining antibodies to native prothrombin by dissociation of antigen antibody complexes formed in the presence of calcium ions with a material having a greater affinity constant for binding with calcium ions than does prothrombin. Dissociation of the complex in this manner yields human native prothrombin antibodies which are specific and non-reactive with human abnormal prothrombin.Type: GrantFiled: October 15, 1984Date of Patent: September 6, 1988Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce E. Furie, Barbara C. Furie, Rita A. Blanchard
-
Patent number: 4639373Abstract: Granulocytes are effectively preserved during storage for long periods of time without freezing by using as the storage medium a non-toxic buffer containing both gelatin and plasma.Type: GrantFiled: July 24, 1985Date of Patent: January 27, 1987Assignee: New England Medical Center Hospitals, Inc.Inventor: Bernard M. Babior